DE3039566A1 - Verfahren zur reinigung von interferon - Google Patents
Verfahren zur reinigung von interferonInfo
- Publication number
- DE3039566A1 DE3039566A1 DE19803039566 DE3039566A DE3039566A1 DE 3039566 A1 DE3039566 A1 DE 3039566A1 DE 19803039566 DE19803039566 DE 19803039566 DE 3039566 A DE3039566 A DE 3039566A DE 3039566 A1 DE3039566 A1 DE 3039566A1
- Authority
- DE
- Germany
- Prior art keywords
- interferon
- solution
- glass beads
- zinc chelate
- beads
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 102000014150 Interferons Human genes 0.000 description 85
- 108010050904 Interferons Proteins 0.000 description 85
- 229940079322 interferon Drugs 0.000 description 83
- 239000000243 solution Substances 0.000 description 81
- 238000000034 method Methods 0.000 description 59
- 239000011324 bead Substances 0.000 description 39
- 230000008569 process Effects 0.000 description 31
- 230000000694 effects Effects 0.000 description 30
- 102000004169 proteins and genes Human genes 0.000 description 25
- 108090000623 proteins and genes Proteins 0.000 description 25
- 239000011701 zinc Substances 0.000 description 24
- 229910052725 zinc Inorganic materials 0.000 description 24
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 22
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 22
- 239000013522 chelant Substances 0.000 description 21
- 239000011521 glass Substances 0.000 description 21
- 238000005406 washing Methods 0.000 description 18
- 239000000047 product Substances 0.000 description 15
- 238000011084 recovery Methods 0.000 description 14
- 238000011282 treatment Methods 0.000 description 14
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 12
- 239000002953 phosphate buffered saline Substances 0.000 description 12
- 239000007853 buffer solution Substances 0.000 description 11
- 238000004140 cleaning Methods 0.000 description 11
- 239000011780 sodium chloride Substances 0.000 description 11
- 102000003996 Interferon-beta Human genes 0.000 description 9
- 108090000467 Interferon-beta Proteins 0.000 description 9
- 239000003463 adsorbent Substances 0.000 description 9
- 238000000746 purification Methods 0.000 description 9
- 239000000126 substance Substances 0.000 description 9
- 239000007795 chemical reaction product Substances 0.000 description 8
- 239000007788 liquid Substances 0.000 description 8
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 8
- 230000002378 acidificating effect Effects 0.000 description 7
- 230000007935 neutral effect Effects 0.000 description 7
- 239000005373 porous glass Substances 0.000 description 7
- 239000007974 sodium acetate buffer Substances 0.000 description 7
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 6
- 238000010828 elution Methods 0.000 description 6
- 235000019624 protein content Nutrition 0.000 description 6
- 238000001179 sorption measurement Methods 0.000 description 6
- 239000002253 acid Substances 0.000 description 5
- 102000006992 Interferon-alpha Human genes 0.000 description 4
- 108010047761 Interferon-alpha Proteins 0.000 description 4
- 206010040914 Skin reaction Diseases 0.000 description 4
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 238000000502 dialysis Methods 0.000 description 4
- 239000007973 glycine-HCl buffer Substances 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 108010058237 plasma protein fraction Proteins 0.000 description 4
- 229940081857 plasma protein fraction Drugs 0.000 description 4
- 230000035483 skin reaction Effects 0.000 description 4
- 231100000430 skin reaction Toxicity 0.000 description 4
- 239000001632 sodium acetate Substances 0.000 description 4
- 235000017281 sodium acetate Nutrition 0.000 description 4
- 239000003381 stabilizer Substances 0.000 description 4
- 239000011592 zinc chloride Substances 0.000 description 4
- 235000005074 zinc chloride Nutrition 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 3
- 239000006145 Eagle's minimal essential medium Substances 0.000 description 3
- 239000004471 Glycine Substances 0.000 description 3
- 229920002684 Sepharose Polymers 0.000 description 3
- PTFCDOFLOPIGGS-UHFFFAOYSA-N Zinc dication Chemical compound [Zn+2] PTFCDOFLOPIGGS-UHFFFAOYSA-N 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- NBZBKCUXIYYUSX-UHFFFAOYSA-N iminodiacetic acid Chemical compound OC(=O)CNCC(O)=O NBZBKCUXIYYUSX-UHFFFAOYSA-N 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000011148 porous material Substances 0.000 description 3
- 230000002285 radioactive effect Effects 0.000 description 3
- 230000009257 reactivity Effects 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical compound [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 2
- 239000004593 Epoxy Substances 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 239000004599 antimicrobial Substances 0.000 description 2
- 238000000376 autoradiography Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000003139 buffering effect Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 239000012467 final product Substances 0.000 description 2
- 238000001502 gel electrophoresis Methods 0.000 description 2
- 229940047124 interferons Drugs 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000001488 sodium phosphate Substances 0.000 description 2
- 229910000162 sodium phosphate Inorganic materials 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 150000003751 zinc Chemical class 0.000 description 2
- 229920000936 Agarose Polymers 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 241000711408 Murine respirovirus Species 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000000842 anti-protozoal effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000003904 antiprotozoal agent Substances 0.000 description 1
- 239000012062 aqueous buffer Substances 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000027455 binding Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000008366 buffered solution Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000009920 chelation Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000011281 clinical therapy Methods 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 238000010908 decantation Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000012149 elution buffer Substances 0.000 description 1
- 125000003700 epoxy group Chemical group 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- ZFKJVJIDPQDDFY-UHFFFAOYSA-N fluorescamine Chemical compound C12=CC=CC=C2C(=O)OC1(C1=O)OC=C1C1=CC=CC=C1 ZFKJVJIDPQDDFY-UHFFFAOYSA-N 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000003966 growth inhibitor Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 229910017053 inorganic salt Inorganic materials 0.000 description 1
- 239000002799 interferon inducing agent Substances 0.000 description 1
- 238000011173 large scale experimental method Methods 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000012487 rinsing solution Substances 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000011172 small scale experimental method Methods 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
- C07K14/565—IFN-beta
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/811—Interferon
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NL7907791A NL7907791A (nl) | 1979-10-23 | 1979-10-23 | Werkwijze voor het zuiveren van interferon. |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE3039566A1 true DE3039566A1 (de) | 1981-05-21 |
Family
ID=19834063
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE19803039566 Withdrawn DE3039566A1 (de) | 1979-10-23 | 1980-10-20 | Verfahren zur reinigung von interferon |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US4359389A (enExample) |
| JP (1) | JPS5673028A (enExample) |
| CA (1) | CA1166959A (enExample) |
| CH (1) | CH647158A5 (enExample) |
| DE (1) | DE3039566A1 (enExample) |
| FR (1) | FR2467602A1 (enExample) |
| GB (1) | GB2061285B (enExample) |
| NL (1) | NL7907791A (enExample) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3225603A1 (de) * | 1981-07-10 | 1983-04-07 | Kuraray Co., Ltd., Kurashiki, Okayama | Kugelfoermige poroese granulate mit einer silanolgruppe auf ihrer oberflaeche sowie ihre verwendung zur herstellung einer blutreinigungsvorrichtung |
| WO2011003600A1 (en) | 2009-07-07 | 2011-01-13 | Biogenerix Ag | METHOD FOR THE PURIFICATION OF INTERFERON-β |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL58765A (en) * | 1979-11-21 | 1986-09-30 | Yeda Res & Dev | Process for the production of essentially pure messenger rna of human fibroblast interferon and process for the production of interferon beta |
| YU45104B (en) | 1980-04-03 | 1992-03-10 | Biogen Nv | Process for producing recombinant dnk molecule, capable of inducting polypeptide expression in an one-cell host |
| JPH0751511B2 (ja) * | 1982-03-15 | 1995-06-05 | 味の素株式会社 | インターロイキン２を含有してなる癌治療剤 |
| JPS58201794A (ja) * | 1982-05-17 | 1983-11-24 | Toray Ind Inc | ヒトインターフェロンβの濃縮精製法 |
| US5643566A (en) * | 1982-09-23 | 1997-07-01 | Cetus Corporation | Formulation processes for lipophilic proteins |
| US4485017A (en) * | 1982-12-22 | 1984-11-27 | Cetus Corporation | Isolation of human interferon by immunosorbent and high performance liquid chromatography |
| IL67896A (en) * | 1983-02-13 | 1987-03-31 | Yeda Res & Dev | Two biologically active human gama interferon subtypes,purification thereof and pharmaceutical compositions containing them |
| CA1231306A (en) * | 1983-03-03 | 1988-01-12 | Erich Hochuli | Purification of interferon |
| US4723000A (en) * | 1983-07-05 | 1988-02-02 | Biospectrum, Inc. | Human interferon gamma and interleukin-2 |
| US4648975A (en) * | 1983-08-17 | 1987-03-10 | Pedro B. Macedo | Process of using improved silica-based chromatographic supports containing additives |
| US4499014A (en) * | 1984-02-07 | 1985-02-12 | Interferon Sciences, Inc. | Method for purifying gamma-interferon |
| US4770781A (en) * | 1986-03-03 | 1988-09-13 | Merck & Co., Inc. | Purification of human interleukin-1 species |
| US4732683A (en) * | 1986-12-02 | 1988-03-22 | Biospectrum, Inc. | Purification method for alpha interferon |
| US4846786A (en) * | 1987-04-30 | 1989-07-11 | Massachusetts Institute Of Technology | Bioreactor containing suspended, immobilized species |
| IT1222427B (it) * | 1987-07-31 | 1990-09-05 | Sclavo Spa | Procedimento per la purificazione di interferone |
| HU201100B (en) * | 1988-03-04 | 1990-09-28 | Egyt Gyogyszervegyeszeti Gyar | Process for large-scale production of high purity human leukocyte alpha interferon with reduced endotoxin content and with improved therapeutic effect |
| EP0551535A1 (en) * | 1992-01-13 | 1993-07-21 | SCLAVO S.p.A. | Process for the purification of recombinant human beta interferon, beta interferon thus purified, and pharmaceutical compositions which contain them |
| US6399296B1 (en) * | 1994-07-20 | 2002-06-04 | The General Hospital Corporation | Interaction trap systems for detecting protein interactions |
| CZ20032526A3 (cs) | 2001-02-27 | 2003-12-17 | Maxygen Aps | Nové molekuly podobné interferonu beta |
| AR034749A1 (es) * | 2001-07-09 | 2004-03-17 | Schering Ag | Formulaciones de interferon beta humano |
| KR100524872B1 (ko) * | 2003-12-04 | 2005-11-01 | 씨제이 주식회사 | 인터페론 베타의 정제방법 |
| KR100524871B1 (ko) * | 2003-12-04 | 2005-10-31 | 씨제이 주식회사 | 인터페론 베타의 정제방법 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1617401A1 (de) * | 1966-05-02 | 1972-02-17 | Centre Nat Rech Scient | Verfahren zur Herstellung von Interferon-Praeparaten |
| US4070284A (en) * | 1973-08-20 | 1978-01-24 | Hitachi, Ltd. | Liquid chromatography and apparatus for the same |
| NL7605805A (nl) * | 1976-05-28 | 1977-11-30 | Stichting Rega V Z W | Werkwijze voor het zuiveren van interferon. |
| DE2961658D1 (en) * | 1978-05-17 | 1982-02-18 | Thomae Gmbh Dr K | Process for preparing human interferon |
-
1979
- 1979-10-23 NL NL7907791A patent/NL7907791A/nl not_active Application Discontinuation
-
1980
- 1980-10-13 GB GB8032954A patent/GB2061285B/en not_active Expired
- 1980-10-17 US US06/198,223 patent/US4359389A/en not_active Expired - Lifetime
- 1980-10-20 DE DE19803039566 patent/DE3039566A1/de not_active Withdrawn
- 1980-10-20 CH CH7806/80A patent/CH647158A5/de not_active IP Right Cessation
- 1980-10-22 FR FR8022617A patent/FR2467602A1/fr active Granted
- 1980-10-23 JP JP14926280A patent/JPS5673028A/ja active Pending
- 1980-10-23 CA CA000363070A patent/CA1166959A/en not_active Expired
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3225603A1 (de) * | 1981-07-10 | 1983-04-07 | Kuraray Co., Ltd., Kurashiki, Okayama | Kugelfoermige poroese granulate mit einer silanolgruppe auf ihrer oberflaeche sowie ihre verwendung zur herstellung einer blutreinigungsvorrichtung |
| WO2011003600A1 (en) | 2009-07-07 | 2011-01-13 | Biogenerix Ag | METHOD FOR THE PURIFICATION OF INTERFERON-β |
| DE102009032179A1 (de) | 2009-07-07 | 2011-01-13 | Biogenerix Ag | Verfahren zur Reinigung von Interferon beta |
Also Published As
| Publication number | Publication date |
|---|---|
| CH647158A5 (de) | 1985-01-15 |
| US4359389A (en) | 1982-11-16 |
| JPS5673028A (en) | 1981-06-17 |
| GB2061285B (en) | 1983-03-30 |
| CA1166959A (en) | 1984-05-08 |
| FR2467602A1 (fr) | 1981-04-30 |
| GB2061285A (en) | 1981-05-13 |
| NL7907791A (nl) | 1981-04-27 |
| FR2467602B3 (enExample) | 1982-07-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE3039566A1 (de) | Verfahren zur reinigung von interferon | |
| DE69424545T2 (de) | Verfahren zur herstellung von immunoglobulin g konzentrat | |
| DE68922358T2 (de) | Chromatographische Trennung von Plasmaproteinen, insbesondere von Faktor VIII, von Willebrand Faktor, von Fibronectin und von Fibrinogen. | |
| EP0447585B1 (de) | Verfahren zur Herstellung eines intravenös verträglichen Immunglobulin-G-Präparates | |
| DE2645466C2 (de) | Verfahren zum Isolieren von Albumin aus Plasmaprodukten | |
| DE2839170C2 (de) | Chromatographisches Material | |
| DE3346336C2 (enExample) | ||
| AT399095B (de) | Verfahren zur auftrennung von proteinen mittels gradientenelution und vorrichtung zur durchführung des verfahrens | |
| DE19937218A1 (de) | Verfahren zur Reindarstellung der den Blutgerinnungsfaktor VII aktivierenden Protease, ihres Proenzyms oder eines Gemisches beider Proteine mittels Affinitätschromatographie | |
| DE69125764T2 (de) | Verfahren zur Herstellung des Von Willebrand-Faktors von höchster Reinheit | |
| DE3149360C2 (enExample) | ||
| EP1005492A1 (de) | Reinigung von von willebrand-faktor durch kationenaustauscherchromatographie | |
| DE2323981C3 (de) | Verfahren zur Isolierung des thrombinartig wirkenden Bestandteils aus dem Gift der Otter Agkistrodon rhodostoma | |
| DE2924744A1 (de) | Verfahren zur reindarstellung von urokinase | |
| DE2551966C3 (de) | Verfahren zum Reinigen von Urokinase | |
| EP1326893A2 (de) | Bikunin enthaltende plasmafraktion, verfahren zu ihrer herstellung und ihrer verwendung | |
| DE2742150A1 (de) | Verfahren zur herstellung von serumalbumin | |
| DE1940130C2 (de) | Verfahren zur Reinigung von Insulin, nach diesem Verfahren gereinigtes Insulin und dessen Verwendung | |
| DE2448371C2 (de) | Verfahren zur Isolierung der Transferrine aus biologischem Material | |
| DE2428955C3 (de) | Verfahren zur Abtrennung der enzymatischen Komponente mit in vivo antikoagulierender und in vitro koagulierender Wirkung aus dem Gift der Schlange Ancistrodon rhodostoma und daraus hergestellte Mittel | |
| DE2732437B2 (de) | Wasserunlösliches Haptoglobinpräparat und Verfahren zu seiner Herstellung | |
| CH575433A5 (en) | Treatment of post-traumatic arthritis - with orgotein | |
| DE2709500C2 (de) | Verfahren zur Reinigung von Heparin | |
| DE69026275T2 (de) | Verfahren zur herstellung von ribonuklease-dimeren | |
| DE68912891T2 (de) | Verfahren zum Beseitigen von Pyrogenen. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8139 | Disposal/non-payment of the annual fee |